BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/31/2015 10:55:00 AM | Browse: 1175 | Download: 1364
 |
Received |
|
2014-11-11 10:20 |
|
Peer-Review Started |
|
2014-11-11 16:15 |
|
To Make the First Decision |
|
2014-12-26 13:14 |
|
Return for Revision |
|
2014-12-30 16:52 |
|
Revised |
|
2015-01-12 06:25 |
|
Second Decision |
|
2015-01-28 11:50 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2015-02-09 10:14 |
|
Articles in Press |
|
2015-02-09 10:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-03-26 19:11 |
|
Publish the Manuscript Online |
|
2015-03-31 10:53 |
| ISSN |
2218-6212 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Neurosciences |
| Manuscript Type |
Minireviews |
| Article Title |
Rituximab in neuromyelitis optica: A review of literature
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ericka Wong, Vijay A Vishwanath and Ilya Kister |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Multiple Sclerosis Society (NMSS) |
|
| Guthy-Jackson Charitable Foundation |
|
|
| Corresponding Author |
Dr. Ilya Kister, MD, Department of Neurology, NYU Multiple Sclerosis Care Center, 240 E 38th St, New York, NY 10026, United States. ilya.kister@nyumc.org |
| Key Words |
Neuromyelitis optica; Rituximab; Longitudinally extensive transverse myelitis; Optic neuritis; CD19+; CD27+ |
| Core Tip |
Relapsing neuromyelitis optica (NMO) is an autoimmune disorder of the central nervous system that often results in severe disability and death if untreated. Rituximab, an anti-CD20 monoclonal antibody, appears to be a promising treatment option for NMO. In this review, we summarize the results of 13 observational studies that assessed efficacy of Rituximab in neuromyelitis optica. On average, 66% of patients remained relapse-free during treatment period and in the majority of patients disability scores have stabilized or improved. Monitoring response to rituximab with CD19+ and CD 27+ cell counts appears to improve outcomes. |
| Publish Date |
2015-03-31 10:53 |
| Citation |
Wong E, Vishwanath VA, Kister I. Rituximab in neuromyelitis optica: A review of literature. World J Neurol 2015; 5(1): 39-46 |
| URL |
http://www.wjgnet.com/2218-6212/full/v5/i1/39.htm |
| DOI |
http://dx.doi.org/10.5316/wjn.v5.i1.39 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
